Best AI News today

tempus ai — AI News Today

248 stories

19 from search

What's happening with tempus ai

We're tracking 248 stories on tempus ai across 77 sources — it's actively developing right now, with 10 published in the last 24 hours. 83 stories have been corroborated by 3+ independent outlets. The most-covered angle right now: Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform (20 sources).

Synthesized live from 77 sources · updated every 15 minutes

248 stories
1 of 5 Top Stories
Breaking
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
BreakingMedia

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

Tempus, the AI-powered cancer diagnostics startup valued at $8.1 billion, is acquiring molecular testing company Personalis in a bid to own the entire precision oncology pipeline—from initial diagnosis through minimal residual disease detection—fundamentally reshaping how cancer treatment decisions get made. The move signals a critical shift in oncology: as AI becomes better at predicting treatment outcomes, the companies that control both the data and the algorithms stand to dominate a market where a single test could determine whether a patient receives chemotherapy or is spared from it. For patients and hospitals already trapped between competing diagnostic platforms, this consolidation raises urgent questions about choice, cost, and whether AI-driven medicine is becoming too concentrated in

Business Wire faviconBusiness Wire·
RelatedTempus AIAI & MoneyAI & Medicine

20 sources

Yahoo Finance faviconYahoo FinanceMedical Device Network faviconMedical Device NetworkMedCity News faviconMedCity News
Media

Tempus AI CEO Eric Lefkofsky sells $827,856 in stock

Investing.com faviconInvesting.com·
RelatedTempus AI
Media

Guardant Suits Against Tempus AI Clear Dismissal Bids

Law360 faviconLaw360·
RelatedTempus AI
Media

15,476 Shares in Tempus AI, Inc. $TEM Bought by Odyssean LLC

MarketBeat faviconMarketBeat·
RelatedTempus AI
Cathie Wood sells $4 million of Tempus AI
Media

Cathie Wood sells $4 million of Tempus AI

Here are Cathie Wood’s latest moves.

TheStreet on MSN faviconTheStreet on MSN·
RelatedTempus AI
Media

Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells 14,286 Shares

MarketBeat faviconMarketBeat·
Media

Tempus AI (TEM) Stock Could Be 33% Undervalued Following Cancer Vaccine News

webull.com faviconwebull.com·
Cathie Wood’s ARK sells Tempus AI stock, buys Veracyte
Media

Cathie Wood’s ARK sells Tempus AI stock, buys Veracyte

Investing.com faviconInvesting.com·
Media

Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?

Yahoo Finance faviconYahoo Finance·
RelatedTempus AI
Tempus AI receives FDA clearance for pulmonary hypertension tool
Media

Tempus AI receives FDA clearance for pulmonary hypertension tool

MobiHealthNews faviconMobiHealthNews·
Down 36%, can Tempus AI stock rebound in late 2026?
Media

Down 36%, can Tempus AI stock rebound in late 2026?

An AI stock sitting in Nancy Pelosi's stock portfolio has slid this year. Here's what her trades and Q2 earnings suggest is next.

TheStreet on MSN faviconTheStreet on MSN·
RelatedTempus AI
Media

Study Backs Efficacy of Tempus AI’s Afib Risk Prediction Technology

Medical Product Outsourcing faviconMedical Product Outsourcing·
Tempus AI (NASDAQ:TEM) Stock Price Down 7.4% - Should You Sell?
Media

Tempus AI (NASDAQ:TEM) Stock Price Down 7.4% - Should You Sell?

MarketBeat faviconMarketBeat·
RelatedTempus AI

4 sources

MarketBeat faviconMarketBeatTradingKey faviconTradingKey
Media

Tempus AI, Inc. Tokenized Stock (Robinhood) Analytics

CryptoRank faviconCryptoRank·
Media

Tempus AI Can’t Shake Guardant Lawsuits Over Diagnostic Tests

Bloomberg Law News faviconBloomberg Law News·
RelatedTempus AI
Tempus AI (TEM) Wins FDA Clearance For ECG Tool That Flags Pulmonary Hypertension
Media

Tempus AI (TEM) Wins FDA Clearance For ECG Tool That Flags Pulmonary Hypertension

Yahoo! Finance Canada faviconYahoo! Finance Canada·
Media

Tracking Cathie Wood: Loading Cerebras System; Selling Off Tempus AI and AMD

Moomoo faviconMoomoo·
Tempus AI Tumbles After Breakneck Rally And Big Deal
Media

Tempus AI Tumbles After Breakneck Rally And Big Deal

TipRanks faviconTipRanks·
Media

Have Tempus AI Insiders Been Selling Stock?

simplywall.st faviconsimplywall.st·

Frequently Asked Questions

What is tempus ai?

tempus ai is a trending topic in artificial intelligence. Best AI News Today aggregates the latest news and developments about tempus ai from over 30 sources including research papers, tech publications, and community discussions.

What are the latest news about tempus ai?

As of today, there are 248 recent stories about tempus ai. Recent headlines include: Tempus AI CEO Eric Lefkofsky sells $827,856 in stock; Cathie Wood’s ARK sells Tempus AI stock, buys Veracyte; Tempus AI, Inc. Tokenized Stock (Robinhood) Analytics. This page is updated every 15 minutes with the latest coverage.

Where can I find tempus ai discussions?

You can find tempus ai discussions on Reddit AI communities, Hacker News, and other tech forums. Best AI News Today aggregates discussions from these platforms alongside research publications and tech media coverage.